

7TH INTERNATIONAL VETERINARY CONGRESS

September 04-05, 2017 | Paris, France

Immunogenicity and safety of the vaccine combination Canigen™ DHPPi and Nobivac™ L4 in dogs

Christelle Fontaine, Severine Arcidiaco, Therese Butaud, Joelle Cronier, Paul Schreiber and Sylvie Gueguen
VIRBAC, France

Introduction: In order to benefit from the widest protection while keeping on a limited number and volume of vaccines administered, mixing of vaccines from different laboratories are commonly performed by veterinarians. The study aim was to confirm the safety and immunogenicity of the vaccines association Canigen™ DHPPi (Virbac) and Nobivac™ L4 (MSD) in dogs.

Methodology: Fifteen SPF male and female Beagle puppies of 9-10 weeks of age on Day 0 participated in this controlled randomized trial. Puppies, received two subcutaneous injections twenty-one days apart for the primary vaccination course. In group 1 (n=5), puppies received one dose of Canigen™ DHPPi vaccine rehydrated with one dose of Nobivac™ L4 vaccine. Puppies belonging to group 2 (n=5) and group 3 (n=5) served as controlled and were vaccinated with respectively Canigen™ DHPPi/L and Nobivac™ DHPPi (MSD) reconstituted with Nobivac™ L4. Puppies were followed for forty-nine days for both, the appearance of any adverse reaction and seroconversion, assessed by either seroneutralisation assays or micro-agglutination tests. Statistical analysis were performed using Unistat 6.0 software. $P < 0.05$ was considered as significant.

Results: On Day 0, none of the puppies (n=0/15) had any antibody against the vaccines strains. After vaccination, no significant difference could be demonstrated between the groups regarding the antibody titres against the core vaccinal strains of Canigen™ vaccine and the *Leptospira* serovars of Nobivac™ vaccine at the times of onset of immunity (Mann-Whitney U test, $p > 0.05$). No general health parameter alteration or local injection site side effect was observed.

Conclusion: Canigen™ DHPPi and Nobivac™ L4 vaccines can be mixed and administered simultaneously to dogs without any major negative impact on the safety and immunogenicity of each respective vaccine.

Biography

Christelle Fontaine is a Medical Manager, Companion Animals, Virbac. She is involved in phase IV trials and collaboration with universities and specialists across the world. She graduated from the French Veterinary School of Maison Alfort, in Paris in 2007.

christelle.fontaine@virbac.com

Notes: